

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : G01T 1/29, 1/203		A2	(11) International Publication Number: WO 96/19739
			(43) International Publication Date: 27 June 1996 (27.06.96)
(21) International Application Number: PCT/EP95/05132			(81) Designated States: AU, CA, JP, KR, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(22) International Filing Date: 22 December 1995 (22.12.95)			
(30) Priority Data: 9425893.6 22 December 1994 (22.12.94) GB			
(71) Applicant (for all designated States except US): KARO BIO AB (SE/SE); Novum, S-141 57 Huddinge (SE).			
(72) Inventors; and (75) Inventors/Applicants (for US only): HAGGBLAD, Johan (SE/SE); Karo Bio AB, Novum, S-141 57 Huddinge (SE). ÖSTERLUND, Marie (SE/SE); Karo Bio AB, Novum, S-141 57 Huddinge (SE).			
(74) Agent: DEAN, John, Paul; Withers & Rogers, 4 Dyer's Buildings, Holborn, London EC1N 2JT (GB).			
Published Without international search report and to be republished upon receipt of that report.			

(54) Title: ASSAY APPARATUS



(57) Abstract

The invention provides a solid support for example for use in a radioligand binding assay, the solid support comprising a plurality of interconnected elements arranged to provide interstitial spaces in which a liquid can flow. When a liquid sample is applied to a surface of the support of the invention it spreads across the surface of the support to a certain extent and also flows into the support on the surfaces of the interconnected elements which form the support and into the interstitial spaces therebetween. The support of the invention may be used as a support for a chemical reaction or for cell growth.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

ASSAY APPARATUS

This invention relates to a solid support which may, in particular, be used as or for an assay apparatus and is particularly, though not exclusively concerned with an assay apparatus for high throughput screening ("HTS") of compounds for pharmaceutical or other properties. The invention also relates to the use of the support as a support for cell growth.

HTS requires automated systems for testing compounds to be screened. Plastic plates containing scintillators have been developed for HTS in which the scintillator is triggered by a radiolabel, such as ^3H . The only radioactivity detected is that bound to a specific binder attached to the plastic surface. Such plates are described in International Patent application no. PCT/FI89/00191.

There has been significant interest recently in the development of so called "free format" assay apparatus which is able to analyze samples presented in different formats, for example, in plates with different numbers of wells.

According to one aspect of the invention there is provided a solid support for example for use in a radioimmunoassay, the solid support comprising a plurality of interconnected elements arranged to provide interstitial spaces in which a liquid can flow. When a liquid sample is applied to a surface of the support of the invention, it spreads across the surface of the support to a certain extent and also flows into the support on the surfaces of the interconnected elements which form the support and into the interstitial spaces therebetween. Preferably, the size of the interconnected elements, and therefore the size of the interstitial spaces, is controlled so that the applied liquid sample is held within the support by surface tension. The size of the interstitial spaces may also be controlled by controlling the packing of the elements.

0 The solid support of the invention has various advantages. For example, the solid support of the invention can be formed into a variety of suitable shapes. In particular, the support may conveniently be provided in the form of a sheet which can be readily cut to size prior to use. This makes the support particularly suitable for use in automated screening systems for HTS, and especially systems using a free format analyzer.

5

The elements which form the solid support of the invention may be porous.

Preferably, the solid support of the invention comprises plastic beads, which may be hollow or porous, sintered or otherwise fused together to form a solid in which the
10 interstitial spaces between the beads can be occupied by a liquid sample applied to a surface of the support. Sintering of the plastic beads may be achieved by temperatures above 200°C together with high pressure or by pressure alone.

15

Typically, the beads will have a diameter in the micrometer to millimetre range.

Where the solid support of the invention is formed from a plastic material, the beads may be made of a plastic material such as polystyrene.

20

Preferably, the solid support of the invention is formed from a plastic scintillation material, that is to say a plastic material including a fluorophore such as diphenyloxazole (PPO) or 1,4-bis-2-(5-phenyloxazolyl)-benzene (POPOP), whereby the material will scintillate in the presence of a suitable radioactive material. Preferably, the radioactive material is a radiolabel present in a sample applied to the support of the invention.

25

Where the support of the invention is used as a scintillation plate, it may be formed from a material which is translucent, more preferably transparent.

30

According to another aspect of the invention there is provided an assay method, the method comprising applying at least one sample to be analyzed to a surface of support in accordance with the invention and assaying the or each sample for the presence or absence of an analyte in the sample and/or for a quantifiable or qualitative effect.

0 The sample may be analyzed several times for different analytes and/or for different quantifiable/qualitative effects, but with only the liquid handling steps for one assay. For example, binding of one hormone labelled with ^{125}I to its receptor and binding of another hormone labelled with ^3H to its receptor in one sample can be measured as ^{125}I and ^3H have different radioactive energies.

5 The support of the invention may be used as a support for a chemical reaction. For example, the support may be used as a support for DNA or polypeptide synthesis.

10 The solid support of the invention may be used advantageously for cell growth. In particular the solid support may be used with certain types of cells which will only express certain proteins when grown in three dimensions as opposed to growth in a two dimensional monolayer. For example, mammary tumour cells will only express lactyl albumin when grown in three dimensions (which is thought to mimic *in vivo* conditions). Thus according to a further aspect of the invention there is provided a growth support

15 comprising a multiplicity of interconnected substantially spherical elements arranged to provide a multiplicity of interstitial spaces therebetween in which cells can grow in, between and/or on the spherical elements. The growth support is advantageous in that a greater amount of cells can be grown in a given unit of surface area compared to two dimensional growth plates. Therefore more growth products can be obtained.

20 According to another aspect of the invention there is provided a method of growing cells, the method comprising growing the cells in the interstitial spaces between the spherical elements or another surface of the growth support of the invention.

25 This is advantageous because it permits the reduction of the reaction volume required. For example, in the experiments below, reaction volumes were reduced from $1\mu\text{l}$ to $30\mu\text{l}$ by placing a disc of the support in the wells of a conventional 24 well assay plate.

30 Whilst there has been a trend towards miniaturization of assay systems for HTS - to 384 and even 864 well plates from 96 well plates or tubes - the instrumentation used for measuring the changes has not kept pace with increasing number of wells tested. In order

0 to reduce assay volume so as to minimize expenditure on reactant and test compounds
Sephadex or Sepharose gel beads have been placed in wells or in larger diameter dishes
such as Petri dishes - "gel permeation" - used for example in melanophore assays.

5 The production of a support in accordance with the invention and its uses will now be
described, by way of example only, with reference to the accompanying drawings, Figs 1
to 4 in which:

Fig 1 is an enlarged cross section through a support in accordance with the invention;

10 Fig 2 is shows the pattern of analyte spread out on the surface of the support of Fig 1; and

Fig. 3 illustrates a binding competition experiment using the support of the present
invention; and

15 Fig. 4 illustrates a dissociation rate experiment using the support of Fig. 3.

MANUFACTURE OF THE PLATE

20 The support 10 shown in Fig 1, which comprises a plate 12, was formed by mixing
Dowex 1-resin (Sigma 1x2-200, dry mesh 100-200, chloride form strongly basic anion
exchange) polystyrene beads, e.g. 14, 16 together with a polystyrene solution. The
polystyrene solution was produced by dissolving either a conventional polystyrene
microtitration plate, a Greiner plate, or ScintiStrips(trade mark) (Wallac) in a solvent
(ethyl acetate). Each polystyrene bead is about 100 μm in diameter.

25 Approximately, 30ml of the resin beads were mixed with 5 ml. of the polystyrene to form
a suspension. The suspension was mixed with a stainless steel spoon and spread out on a
sheet of aluminium foil as an even layer approximately 2 mm thick. The layer was dried at
about 70°C on a thermostated hot plate to form a spongy plate. The aluminum foil was
then carefully removed. The side of the plate which had faced the aluminum foil was
30 relatively impervious, whereas the porous nature of the other major face of the plate was
clearly apparent.

0 A plate formed using dissolved ScintiStrips was highly fluorescent in UV light whereas a plate formed using dissolved Grenier plates was not as fluorescent under the same conditions.

5 When a drop of liquid sample is applied to the surface 18 of the support 10, it spreads across the surfaces shown in Fig 2, which shows coloured saline spots applied to the surface of the plate and also enters the interstitial spaces between the sintered beads. After a number of samples have been applied to the plate, it can be used with a suitable free format scintillation counter to determine the amount of radioactive label in the sample. The sample is localized within the support by surface tension, avoiding the need for a
10 plate containing discrete wells. This facilitates the use of the plate in automated screening systems for HTS.

RECEPTOR BINDING EXPERIMENTS

15 A fluorescent plate in accordance with the invention was manufactured as described above, using dissolved ScintiStrips, and then cut in half.

In order to confirm that the test specificity of [3H]-estradiol was binding to the receptor rather than the plastic support and to test competition and binding kinetics, a support in the form of a sheet was made as described above. Human estrogen receptor hormone binding
20 domain (hER-HBD) in yeast extracts was diluted 1:100 in regular phosphate buffered saline (PBS). A SPLAT sheet was incubated with the receptor solution without any washing steps of the sheet prior to receptor incubation. A non-programmed yeast extract and plain PBS were used as controls. The sheets were incubated for a total of four days to allow adsorption of protein.

25 On the day of the binding experiments, the sheets were not washed but simply punched to produce tablets (3 mm in diameter and 1.5 mm thick). The tablets were put into wells of a 24-well dish.

30 Binding experiment 1:

A binding competition curve was constructed where 30 μ l of reaction solution was put onto

0 each tablet. The tablets were divided into three groups: 1) hER-HBD, 2) non-prog. yeast
and 3) plain buffer. The same series of samples were used with all three groups. The
samples consisted of PBS with one concentration of radioligand ([3-H]-estradiol; 5 mM)
and one given concentration of diethylstilbestrol (DES) in a series of concentrations (0.7,
5 7, 70, 700 and 7000 nM and no DES). After putting on the sample with a Finnpiptette, the
tablets were incubated at room temperature for 2 hours. The sheets were measured in a
Wallac Microbeta. Data was analysed using Excel (Microsoft, USA). It is significant to
note that there was no need to wash the tablets prior to analysis, and plotted using
Kaleidagraph.

10 Figure 4 shows the results of the equilibrium binding competition experiment. There was
no binding of [3H]-estradiol to tablets that were incubated with non-programmed yeast
extract or with plain PBS. There was, as expected, binding of [3H]-estradiol to sheets
treated with hER-HBD. With the latter there was also a concentration dependent inhibition
of binding of [3H]-estradiol by DES.

15

Binding experiment 2:

hER-HBD tablets that had maximal binding-levels in experiment 1, above, were put into
the position in a 24-well plate for counting of dissociation rates. To the tablets were added
100 µl of the [3H]-estradiol-only solution used above (vehicle) or the vehicle plus a 3000x
20 excess of DES. Each tablet was now floating in solution. In the experiment 1, above, all
solution was absorbed. The scintillation of the tablets was counted repeatedly once every
15 seconds for approximately 30 minutes in a Wallac Microbeta. Data was handled using
Excel and plotted using Kaleidagraph.

25 [3H]-estradiol bound to the receptors declined bi-exponentially as previously described
(Häggblad J, Carlsson B & Raynaud J-P (1994) Evaluation of conformational changes in
hER-HBD by pharmacological dissection of hormone dissociation rates in a homogeneous
hormone binding assay. In : Proceedings; Hormonal Carcinogenesis. Springer Verlag (in
press)) in the DES containing solution (Figure 4). With the solution containing [3H]-
30 estradiol only, there was association of [3H]-estradiol to the receptors.

0 The first result is a typical dissociation curve. The second result is more complex and probably reflects a binding of radioligand to as yet unoccupied sites on the tablets. The latter result suggests that there is an excess of receptors over radioligand and that a new state can be reached by the addition of [3H]-estradiol.

5 The above results confirm binding of [3H]-estradiol using the support of the invention is to hER-HBD and not to the plastic or to yeast proteins; i.e. [3H]-estradiol binding is specific to receptors. Furthermore, it has been demonstrated that the format of the present invention works in both equilibrium and in kinetic experimental situations, and that it is a very robust format since no washing steps were required during this set of experiments.

10 **Figure legends:**

Figure 1. Binding competition curve in the SPLAT format. SPLAT tablets were pretreated with hER-HBD (yeast) or with yeast extract or simple PBS. There is only binding of [3h]-estradiol to hER-HBD pre-treated tablets. The binding of [3H]-estradiol is inhibited by diethylstilbestrol.

15 Figure 2. Dissociation rate experiment with [3H]-estradiol liganded hER-HBD pre-treated SPLAT tablets. Diethylstilbestrol induces dissociation of [3H]-estradiol. Addition of [3H]-estradiol only, causes association which is explained by an excess of unoccupied receptors to radioligand ([3H]-estradiol).

20 Whilst in the above example radioactivity was measured using discrete discs cut from a plate of the present invention, it will be appreciated that preferably an entire plate may be analysed using a free format counter such as an image-enhanced CCD camera.

25 In an alternative embodiment, the beads which form the basis for the support may contain a fluorophore such as diphenyloxazole (PPO) or 1,4-bis-2-(5-phenyloxazolyl)-benzene (POPOP), which will scintillate in the presence of a suitable radioactive material.

Typically, the radioactive material is a radiolabel present in a liquid sample applied by a pipette to the support.

- 0 The surface of the plate may be treated chemically or physically by known means to enhance the binding of cells or other molecules to the surface.

The solid support described above may be used as a growth support for cells preferably if it is made from beads lacking a fluorephore.

5

A rigid support in accordance with the invention may also be provided in which the interstitial spaces between the elements are in the form of capillaries.

0

CLAIMS

5

1. A solid assay support comprising a plurality of interconnected elements arranged to provide interstitial spaces in which a liquid can flow.

10

2. A solid assay supporting according to claim 1 in which the elements are substantially spherical.

3. A solid assay support according to claim 1 or 2 in which the size of the interconnected elements and therefore the size of the interstitial spaces is controlled whereby an applied liquid sample is held on or within the support by surface tension.

15

4. A solid assay support according to claim 1, 2 or 3 is in the form of a sheet.

5. A solid assay support according to claim 4 which can be readily cut to size prior to use.

20

6. A solid assay support according to any preceding claim in which the elements which form the support are porous.

7. A solid assay support according to any preceding claim in which the interconnected elements which form the solid support of the invention comprises plastic beads.

25

8. A solid assay support according to claim 7 in which the beads are made of a polystyrene.

9. A solid assay support according to any preceding claim in which the elements which form the support are fused or sintered together to form a solid.

30

10. A solid assay support according to any preceding claim in which the elements forming the support have a diameter in the micrometer to millimetre range.

0

11. A solid assay support according to any preceding claim which is formed from a plastic scintillation material.

5

12. A solid assay support according to claim 11 in which the plastic material includes a fluorophore.

13. A solid assay support according to claim 12 in which the fluorophore is diphenyloxazole (PPO) or 1,4-bis-2-(5-phenyloxazolyl)-benzene (POPOP).

10

14. A solid assay support according to claim 11, 12, or 13 in which the support will scintillate in the presence of a suitable radioactive material present in a sample applied to the support.

15

15. A solid assay support according to any preceding claim which is translucent.

16. A solid assay support according to claim 14 which is transparent.

20

17. An assay method comprising applying at least one sample to be analyzed to a surface of a support in accordance with any preceding claim and assaying the or each sample for the presence or absence of an analyte in the sample and/or for a quantifiable or qualitative effect.

18. An assay method according to claim 16 in which the sample is in liquid form.

25

19. A solid support for a chemical reaction, the solid support comprising a plurality of interconnected substantially spherical elements.

20. A support according to claim 16, for use as a support for DNA or polypeptide synthesis.

30

21. A cell growth support comprising a multiplicity of interconnected substantially

0 spherical elements arranged to provide a multiplicity of interstitial spaces
therebetween in which cells can grow in, between and/or on the spherical elements.

22. A method of growing cells, the method comprising growing the cells on and/or in
the cell growth support of claim 18.

5 23. A method of growing cells according to claim 19 in which the cells are grown in
the interstitial spaces of the cell growth support.

10 24. The combination of one or more assay supports in accordance with any one of
claims 1 to 16 with a multiwell plate or dish in which individual supports are
placed in at least one well of the plate to reduce the volume of the well.

1 / 3

FIG. 1.





FIG. 2.



2 / 3

Binding competition test with SPLAT-tablets treated with hER-HBD extract, non-programmed yeast extract or plain buffer

Five concentrations of diethylstilbestrol, one concentration [3H]estradiol (=5 nM)




FIG. 3.

3 / 3

Simple binding kinetics; SPLAT-tablets with hER-HBD were treated with 30 μ l 5 nM [3H]-estradiol. At steady-state a binding inhibitor was added at 3000x excess and compared to addition of vehicle alone





FIG. 4.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: G01T 1/29, 1/203, C12M 3/00	A3	(11) International Publication Number: WO 96/19739 (43) International Publication Date: 27 June 1996 (27.06.96)
(21) International Application Number: PCT/EP95/05132 (22) International Filing Date: 22 December 1995 (22.12.95) (30) Priority Data: 9425893.6 22 December 1994 (22.12.94) GB (71) Applicant (for all designated States except US): KARO BIO AB [SE/SE]; Novum, S-141 57 Huddinge (SE). (72) Inventors; and (75) Inventors/Applicants (for US only): HAGGBLAD, Johan [SE/SE]; Karo Bio AB, Novum, S-141 57 Huddinge (SE). ÖSTERLUND, Marie [SE/SE]; Karo Bio AB, Novum, S-141 57 Huddinge (SE). (74) Agent: DEAN, John, Paul; Withers & Rogers, 4 Dyer's Buildings, Holborn, London EC1N 2JT (GB).		(81) Designated States: AU, CA, JP, KR, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 14 November 1996 (14.11.96)

(54) Title: ASSAY APPARATUS



(57) Abstract

The invention provides a solid support for example for use in a radioligand binding assay, the solid support comprising a plurality of interconnected elements arranged to provide interstitial spaces in which a liquid can flow. When a liquid sample is applied to a surface of the support of the invention it spreads across the surface of the support to a certain extent and also flows into the support on the surfaces of the interconnected elements which form the support and into the interstitial spaces therebetween. The support of the invention may be used as a support for a chemical reaction or for cell growth.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Larvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

INTERNATIONAL SEARCH REPORT

Int Application No
PCT/EP 95/05132A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 G01T1/29 G01T1/203 C12M3/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 G01T

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 381 921 A (PIERCE ZONA R ET AL) 3 May 1983 see column 8, line 24 - line 46; figure 1 see column 9, line 38 - line 42	1,2,4,5, 7
X	see column 13, line 5 - line 14 see column 21, line 32 - line 38	8
X	see column 21, line 46 - line 66; figure 4	3
A	see column 27, line 7 - line 12	11
A	see column 31, line 45 - line 56; figure 12	11

X	US 4 692 266 A (COSTA LORENZO F ET AL) 8 September 1987 see column 5, line 25 see column 6, line 7 - line 15 see column 6, line 35 - column 7, line 2; claims 1,11; figures 1-3 see column 5, line 41 ---	1,11-13

	-/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

Date of the actual completion of the international search

28 May 1996

Date of mailing of the international search report

04. 10. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

HOCQUET, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 95/05132

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 357 400 A (CHOLESTECH CORP) 7 March 1990 see page 4, line 6 - line 10 ---	1-5,7,9, 17-19
X	US 4 450 239 A (CHATTERTON ROBERT T) 22 May 1984 see column 3, line 20 - line 23 ---	1,2
X	US 4 430 436 A (KOYAMA MIKIO ET AL) 7 February 1984 see column 3, line 68 - column 4, line 69 see column 4, line 29 - line 56 see column 11, line 48 - column 12, line 12 see column 13, line 54 - line 55 see column 14, line 6 - line 33 ---	1
X	US 5 268 301 A (POTTER COLIN G) 7 December 1993 see column 2, line 60 - column 3, line 2 see column 3, line 31 - line 46 see column 3, line 56 - line 60 see column 1, line 35 - line 68 ---	19,20
A	EP 0 127 170 A (FUJI) 5 December 1984 see page 15, line 35 - page 16, line 7 ---	1,11
A	WO 90 03844 A (WALLAC OY) 19 April 1990 cited in the application see page 1, line 11 - line 16 ---	11
A	US 4 304 865 A (NATIONAL RESEARCH DEVELOPMENT CORPORATION) 8 December 1981 see column 3, line 9 - line 13 see column 5, line 66 - column 6, line 10 -----	11,17, 19,24
A		24

INTERNATIONAL SEARCH REPORT

ernational application No.

PCT/EP 95/ 05132

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. CLAIMS 1-20,24 SOLID ASSAY SUPPORT FORMED OF A PLURALITY OF INTERCONNECTED ELEMENTS, FORMED FROM PLASTIC SCINTILLATION MATERIAL.
2. CLAIMS 21-23 CELL GROWTH SUPPORT

FOR FURTHER INFORMATION PLEASE SEE FORM PCT/ISA/206 MAILED 20.06.96

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-20,24

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 95/05132

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4381921	03-05-83	US-A- 4258001	24-03-81
		CA-A- 1124644	01-06-82
		EP-A- 0013156	09-07-80
		JP-C- 1497427	29-05-89
		JP-A- 55090859	09-07-80
		JP-B- 63043701	01-09-88
		US-A- 4357363	02-11-82

US-A-4692266	08-09-87	CA-A- 1268937	15-05-90
		EP-A- 0212450	04-03-87
		JP-A- 62156189	11-07-87

EP-A-0357400	07-03-90	US-A- 5156954	20-10-92
		AU-B- 625973	23-07-92
		AU-A- 4209089	23-03-90
		WO-A- 9002200	08-03-90
		US-A- 5171688	15-12-92
		JP-A- 2299597	11-12-90

US-A-4450239	22-05-84	CA-A- 1182044	05-02-85
		EP-A- 0075193	30-03-83
		GB-A,B 2106646	13-04-83
		US-E- RE32557	08-12-87

US-A-4430436	07-02-84	JP-C- 1592844	14-12-90
		JP-B- 2019904	07-05-90
		JP-A- 57101761	24-06-82
		DE-A- 3150102	29-07-82

US-A-5268301	07-12-93	NONE	

EP-A-127170	05-12-84	JP-C- 1691093	27-08-92
		JP-B- 3060071	12-09-91
		JP-A- 59218977	10-12-84
		US-A- 4916321	10-04-90

WO-A-9003844	19-04-90	AU-A- 4416589	01-05-90
		DE-D- 68915771	07-07-94
		DE-T- 68915771	20-10-94
		EP-A- 0438470	31-07-91

INTERNATIONAL SEARCH REPORT

Information on patent family members

In Application No

PCT/EP 95/05132

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9003844		SE-A- 8803602	11-10-88

US-A-4304865	08-12-81	EP-A- 0009320	02-04-80
		GB-A,B 2028869	12-03-80

THIS PAGE BLANK (USPTO)